fb

ACCA AUTUMN SAVINGS 20% OFF

What would you prefer – cheap drugs or new drugs?

What would you prefer – cheap drugs or new drugs?

Whilst the answer would to a certain extent depend on your personal situation, it’s one of the challenges currently facing the pharmaceutical industry.

The major pharmaceutical companies all have significant research and development (R&D) expenses. It’s been estimated that to get a new medicine onto the market from scratch it costs over £1 billion on average.

That’s a lot of R&D and importantly for the drugs companies, it’s a lot of expenses that need to be recovered.

So how do they recover their R&D expenses?

Well, their hope is that they have various “blockbuster drugs” that will treat or cure some of the more common medical problems and will generate significant amounts of revenue.

The challenge for these drug companies though is that if they spend a significant amount on R&D to discover a drug which is going to enable them to recover these R&D expenses (plus generate a profit), they will be a bit disappointed if other drug companies develop cheap versions of these drugs once they’ve been discovered.

In other words, these other companies won’t have the significant R&D expenses and instead will just copy the newly discovered drugs and get the revenue in.

The pharmaceutical industry tries to get around this problem by providing a 10 to 15 year “patent period” after discovery of the drug whereby other companies cannot copy it.

The giant pharmaceutical company Pfizer has a blockbuster drug called Lipitor (it helps reduce cholesterol) and this is about to come out of its patented protection. The drug was first invented in the 1980s and since then it has reportedly generated more than $125 billion of revenue for Pfizer.

Whilst this has been an extremely successful drug for Pfizer (it accounted for 15% of their revenue last year) things are going to change dramatically in the near future.

As soon as the patent protection period ends next week for the drug, other drug companies will make cheap (but still effective) copies of the drug and it is estimated that the price will fall by 85%.

This in itself highlights an interesting ethical discussion surrounding pharmaceutical companies.

Namely, should they be able to enjoy the benefit of a patent protection to enable them to keep prices high so that they can put money back into R&D or are they making significant profits by pricing the drugs out of the reach of a lot of people around the world?

Share this entry

Recent articles

View All Articles
Two jobs, one big mistake…
Sep 10, 2025
Title
Two jobs, one big mistake…
Excerpt

Can you really hold down two full-time jobs at the same time? For most of us, it sounds […]

Cash is (no longer) King…
Sep 08, 2025
Title
Cash is (no longer) King…
Excerpt

For generations, a wallet or purse has been an everyday essential — a small, leather-bound companion holding coins, […]

Nestlé CEO fired over office relationship…
Sep 04, 2025
Title
Nestlé CEO fired over office relationship…
Excerpt

Nestlé is the world’s largest food and beverage company, with a portfolio that includes some of the most […]

When ethical claims backfire: Armani’s €3.5m fine
Aug 20, 2025
Title
When ethical claims backfire: Armani’s €3.5m fine
Excerpt

Luxury brands are often seen as the gold standard of quality, exclusivity, and prestige. They charge premium prices […]

The benefits of sleeping on the job…
Jul 21, 2025
Title
The benefits of sleeping on the job…
Excerpt

My guess is that not a lot of you have gone up to your boss and said that […]

A car wash, wallet and apartment – laundering explained…
Jul 18, 2025
Title
A car wash, wallet and apartment – laundering explained…
Excerpt

Money laundering might sound like something from a gangster movie, but it’s a serious real-world issue that affects […]

Take a selfie and then return it…
Jul 16, 2025
Title
Take a selfie and then return it…
Excerpt

The latest must-have outfit trending on TikTok might be out of fashion by the time it arrives on […]

When auditors overstay their welcome…
Jul 11, 2025
Title
When auditors overstay their welcome…
Excerpt

A cornerstone of audit is independence. A recent stumble by EY – one of the Big Four accounting […]